Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Network
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…
Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Network
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in Maryland: - Johns Hopkins Univ/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…
Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Sites in Maryland: - Investigative Site — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Maryland: - Local Institution - 2133 — Baltimore, Maryland
Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
Sponsor: Pierre Fabre Medicament
NCT ID: NCT04554914
Sites in Maryland: - University of Maryland Medical Center (Adults only) — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants wi…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05734066
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 2 Recruiting NIH
This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type of cancer.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05333458
Sites in Maryland: - National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activat…
Sponsor: Carl Allen
NCT ID: NCT04079179
Sites in Maryland: - John Hopkins University School of Medicine — Baltimore, Maryland
Phase 2 Recruiting Network
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sponsor: AIDS Malignancy Consortium
NCT ID: NCT04305691
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Sponsor: USWM CT, LLC
NCT ID: NCT05642455
Sites in Maryland: - National Institutes of Health — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Academic/Other
This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT03465592
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07223047
Sites in Maryland: - Local Institution - 0009 — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT01804634
Sites in Maryland: - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV. KS tumors usually involve the skin, but may also involve lymph nodes, lungs, bone, and gastrointe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04941274
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body. These cancers may have mutations in a gene called IDH2. Res…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06176989
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus. People infected with human immunodeficiency virus (HIV…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07308886
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among people living with HIV or those with prior history of transplant…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04303117
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is inje…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06503146
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV. These diseases cause severe inflammation that can be fatal if not…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06052618
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are aggressive forms of cancer that affects cells in the immune system and lymph nodes. How they develop is not well unders…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05907759
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Maryland: - Johns Hopkins School of Medicine — Baltimore, Maryland
Phase 1 Recruiting NIH
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04704661
Sites in Maryland: - National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland